APA
Khanim F. L., Merrick B. A. M. E., Giles H. V., Jankute M., Jackson J. B., Giles L. J., Birtwistle J., Bunce C. M. & Drayson M. T. (20121002). Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. : Blood cancer journal.
Chicago
Khanim F L, Merrick B A M E, Giles H V, Jankute M, Jackson J B, Giles L J, Birtwistle J, Bunce C M and Drayson M T. 20121002. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. : Blood cancer journal.
Harvard
Khanim F. L., Merrick B. A. M. E., Giles H. V., Jankute M., Jackson J. B., Giles L. J., Birtwistle J., Bunce C. M. and Drayson M. T. (20121002). Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. : Blood cancer journal.
MLA
Khanim F L, Merrick B A M E, Giles H V, Jankute M, Jackson J B, Giles L J, Birtwistle J, Bunce C M and Drayson M T. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. : Blood cancer journal. 20121002.